Company: Dana-Farber Cancer Institute
Job title: Director - Center For Patient Derived Models, Principal Investigator, Neuropathologist & Pathologist
Keith L. Ligon is Director of the DFCI Center for Patient Derived Models and a board-certified Neuropathologist with expertise in brain tumor research. He holds joint appointments at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute. He is a founding Board Member of the Society for Functional Precision Medicine. He has made essential contributions in diagnostics and targeted therapy of gliomas and precision medicine. His lab has focused on generation and investigation of patient derived models of glioma and has generated more than 1000 patient models of brain cancer and has utilized these for preclinical studies of novel therapies. He serves as PI for several NIH grants and serves as co-director for the NCI Broad-DFCI Cancer Model Development Center within the Human Cancer Models Initiative. He also has leadership roles and participation in pathology and biomarker research within several independent and NCI sponsored clinical trial consortia (DIPG-BATS, PNOC, COG, ABTC, Alliance, Ivy Foundation).
Brain Tumor Models as a Platform to Advance Functional Diagnostics & Clinical Trials 2:15 pm
• Models of primary and metastatic brain cancer are highly valuable tools for precision medicine and preclinical testing • Large number of common and rare brain cancer models allow large scale drug screening • Novel approaches and technologies emerging to test patient models to personalize medicine and trialsRead more
day: Day Two